Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019 May;25(5):955-964.
doi: 10.1016/j.bbmt.2018.12.765. Epub 2018 Dec 31.

Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results

Affiliations
Multicenter Study

Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results

Michael A Pulsipher et al. Biol Blood Marrow Transplant. 2019 May.

Abstract

Although donation of bone marrow (BM) or peripheral blood stem cells (PBSCs) from children to family members undergoing allogeneic transplantation are well-established procedures, studies detailing levels of pain, symptoms, and long-term recovery are lacking. To address this lack, we prospectively enrolled 294 donors age <18 years at 25 pediatric transplantation centers in North America, assessing them predonation, peridonation, and at 1 month, 6 months, and 1 year postdonation. We noted that 71% of children reported pain and 59% reported other symptoms peridonation, with resolution to 14% and 12% at 1 month postdonation. Both older age (age 13 to 17 years versus younger) and female sex were associated with higher levels of pain peridonation, with the highest rates in older females (57% with grade 2-4 pain and 17% with grade 3-4 pain). Multivariate analyses showed a 4-fold increase in risk for older females compared with males age <13 years (P <.001). At 1 year, 11% of 13- to 17-year-old females reported grade 2-4 pain, compared with 3% of males age 13 to 17 years, 0% of females age <13 years, and 1% of males age <13 years (P = .01). Males and females age 13 to 17 years failed to return to predonation pain levels at 1 year 22% and 23% of the time, respectively, compared with 3% and 10% in males and females age <13 years (P = .002). Our data show that females age 13 to 17 years are at increased risk of grade 2-4 pain at 1 year and >20% of females and males age 13 to 17 years do not return to baseline pain levels by 1 year after BM donation. Studies aimed at decreasing symptoms and improving recovery in older children are warranted.

Keywords: BM collection toxicities; Donor safety; PBSC collection toxicities; Stem cell transplantation.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURES OF CONFLICT OF INTEREST

None of the authors have any conflict of interest to declare.

Figures

Figure 1.
Figure 1.. Location and grade of pain and type and grade of collection related toxicities reported by children within 48 hours after bone marrow collection by age group.
A. Sites of pain among BM donors B. Collection related toxicities among BM donors
Figure 2.
Figure 2.. Overall highest reported grade of pain and symptoms by age at pre-collection, within 48 hours of collection and at 1month, 6months, and 1 year after first BM collection procedure.
A. Skeletal Pain. Skeletal pain experienced by BM donors, by age, at pre-collection, during the peri-collection period, and post-donation. (Skeletal pain represents pain in at least one of the following sites: back, bone, headache, hip, limb, joint, and neck). The severity of skeletal pain is defined as the maximum grade among these pain sites. B. Max MTC. Symptoms experienced by BM donors, by age, at pre-collection, during the peri-collection period, and post-donation. (Max MTC represents: fatigue, insomnia, site reaction, dizziness, anorexia, nausea, vomiting, skin (rash), fever, syncope). The severity of max MTC is defined as the maximum grade among these symptoms.

Comment in

References

    1. Pulsipher MA, Nagler A, Iannone R, et al. Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatr Blood Cancer. 2006;46:422–33. - PubMed
    1. Pulsipher MA, Levine JE, Hayashi RJ, et al. Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: the pediatric blood and marrow transplant consortium experience (PBMTC) 1996–2003. Bone Marrow Transplant. 2005;35:361–7. - PubMed
    1. Styczynski J, Balduzzi A, Gil L, et al. Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party study. Blood. 2012;119:2935–42. - PubMed
    1. Frangoul H, Nemecek ER, Billheimer D, et al. A prospective study of G-CSF primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study. Blood. 2007;110:4584–7. - PubMed
    1. Children as hematopoietic stem cell donors. Pediatrics. 2010;125:392–404. - PMC - PubMed

Publication types